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Clinical Case Report
ABSTRACT
B-cell prolymphocytic leukemia (B-PLL) is an extremely rare disease, accounting for approximately 1% of the lymphocytic 
leukemias. B-PLL generally occurs in older people. It is characterized by the presence of more than 55% prolymphocytes in 
the peripheral blood (PB), no or minimal lymphadenopathy, massive splenomegaly, and very high white blood cell counts. 
The prognosis of B-PLL patients is generally poor, with a median survival of 3 years, although a subset of patients may 
show a prolonged survival. Herein, we report a case of a 70-year-old male with weakness, generalized lymphadenopathy, 
and moderate splenomegaly at the initial presentation. Hematologic examination revealed lymphocytic leukocytosis, 
favoring a chronic lymphoproliferative disorder (CLPD). The key to decoding the precise CLPD was a combination of the 
clinical profile, morphologic findings on the peripheral blood and the bone marrow, immunophenotypic analysis, and 
cytogenetic study. The best diagnosis proffered was a de novo chronic lymphocytic leukemia/prolymphocytic leukemia. 
There was no prior history of lymphoproliferative disorder or lymphocytic leukocytosis. Discriminating this entity from other 
lymphoproliferative disorders is crucial as the treatment and prognosis are varied compared to the other lymphoproliferative 
disorders. The diagnostic conundrum encountered and the incredible utility of ancillary studies in such a scenario are 
highlighted in this study. 
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INTRODUCTION
B-cell prolymphocytic leukemia (B-PLL) is a 
sporadic lymphoproliferative disorder, accounting 
for < 1% of all the mature B cell malignancies.1 It is 
thought to arise de novo because the progression 
of chronic lymphocytic leukemia (CLL) into B-PLL 
does not occur by definition.2 It is characterized 
by neoplastic proliferation of prolymphocytes with 
prominent splenic involvement. The critical distinction 
of B-PLL from CLL and Chronic lymphocytic leukemia/
Prolymphocytic leukemia (CLL/PLL) is based on the 
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percentage of prolymphocytes in the peripheral 
blood. Accordingly, the FAB (French American British) 
group proclaimed the following classification, which 
is universally accepted:2,3 (i) Chronic Lymphocytic 
Leukemia (CLL): when prolymphocytes are ≤ 10% of 
lymphoid cells; (ii) CLL-PLL: when prolymphocytes are 
11-55%; (iii) PLL: when prolymphocytes are > 55% 
of lymphoid cells.
Other chronic lymphoproliferative disorders 
(CLPDs) also obfuscate the picture of B-PLL and CLL/PLL. 
The distinction is crucial given the different therapeutic 
strategies for the various LPDs. Herein, we report a 
case of CLPD in this context, and attempt to bring 
forth the diagnostic perils, and also the pointers to 
unravel the dilemma.
Case Report
A 70-year-old male presented at our institute with 
decreased appetite and generalized weakness for the 
past 4 weeks. He did not complain of fever and weight 
loss. On examination, multiple bilateral axillary, cervical, 
inguinal, and left supraclavicular lymphadenopathy 
(largest measuring 2.5 x 2 cm) were noted, along with 
moderate splenomegaly. The patient had no prior 
history or documentation of lymphocytic leukocytosis 
or any relevant illness. Hematological parameters 
revealed macrocytic anemia [Hemoglobin: 4.8g/dl 
(reference range [RR], 12-17g/dl), Mean Corpuscular 
Volume: 120fl (RR, 80-100fl), Mean Corpuscular 
Hemoglobin: 40pg (RR, 27-32pg), Mean Corpuscular 
Hemoglobin Concentration: 33% (RR, 31-35%)], 
thrombocytopenia [Platelet count: 30,000/μL (RR, 
150000-400000/μL) and leukocytosis [Total Leucocyte 
Count: 21,000/μL (RR, 4000-11000/μL)] with 80% 
atypical lymphocytes. Analysis of the lymphoid 
morphology divulged two population of cells, the 
predominant (70% of lymphoid cells) being small 
atypical lymphocytes having round nuclei, clumped 
chromatin and scant cytoplasm, while the other sort 
(30% of lymphoid cells) constituted medium-sized 
cells (twice the size of a small lymphocyte) with a 
round to indented nucleus, moderately condensed 
nuclear chromatin, prominent central nucleolus and 
a moderate amount of cytoplasm (Figure 1A). These 
latter cells were fancied to be prolymphocytes, and a 
diagnosis of CLPD was suspected. The flow cytometric 
analysis was advised for confirmation and subtyping. 
Since the flow cytometric lymphoma panel in our 
resource-limited setting did not comprise the required 
armamentarium to conclusively distinguish between 
the relevant CLPDs in our context, bone marrow 
aspiration, and especially, a biopsy was sought in the 
hope that immunohistochemistry (IHC) could provide 
succor by providing the requisite immunomarkers, 
although as per the International Workshop on CLL 
(iwCLL) guidelines a bone marrow aspirate and biopsy 
are generally not required for the diagnosis of CLL/
PLL.. The bone marrow study disclosed a hypercellular 
Figure 1. A – Photomicrograph of peripheral blood smear showing lymphocytosis comprising atypical lymphoid 
cells; B – Photomicrograph of bone marrow aspirate exhibiting dual population of atypical lymphoid cells – small CLL 
lymphocyte (arrow) and prolymphocytes (arrowheads) [Leishman stain (A) X400, (B) X1000].
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marrow diffusely infiltrated by atypical lymphoid 
cells (83%), suppressing the normal hematopoietic 
elements. Appraisal of the lymphoid cells unveiled 
the same morphology discerned in the peripheral 
blood; however, the differential count was altered. 
The majority (68%) of these lymphoid cells were 
the medium-sized cells, while the remaining (32%) 
comprised the small atypical lymphocytes (Figure 1B). 
In addition, a megaloblastic picture in the erythroid 
series was identified, accounting for the macrocytic 
anemia. The coagulation profile, liver and renal 
function tests, viral markers (for hepatitis B, hepatitis 
C, and HIV) and autoimmune profile (ANA and ANCA) 
were unremarkable. The abdominal ultrasonography 
conf i rmed moderate splenomegaly and mi ld 
hepatomegaly.
The flow cytometry of the bone marrow aspirate 
sample was performed on the four-color enabled 
BD-FACS Caliber Flow cytometer using the standard 
lyse-wash-stain procedure. Data were analyzed using 
the CellQuest Pro Software. The abnormal bright 
CD-45 positive cells exhibiting low to moderate 
Forward Scatter and low Side scatter were gated 
(63%).
The gated cells showed moderate intensity for 
CD 19, CD 20, CD 22 and kappa. A subset of these 
cells was positive for CD 79a; while CD 3, CD 4, CD 8, 
CD 10, CD 11c, CD 103, CD 34 and lambda were 
negative [All antibodies from BD Biosciences, San Jose, 
CA, USA]. The immunophenotype was consistent with 
a mature B-cell CLPD (Figure 2A and 2B).
IHC on the bone marrow biopsy demonstrated the 
atypical lymphoid cells to be negative for Cyclin D1 and 
positive for CD 5 (Figure 3A, 3B, and 3C). Cyclin D1 
was resorted to by IHC on the marrow biopsy in view 
of the absence of CD 23 in the flow cytometry panel, 
with respect to mantle cell lymphoma.
Correlating with the clinical findings of generalised 
lymphadenopathy and moderate splenomegaly 
(at the first presentation), hematological parameters, 
morphology and percentage of the abnormal lymphoid 
cells in the peripheral blood and bone marrow, flow 
cytometry analysis and IHC study on the marrow 
biopsy, a final diagnosis of CLL/PLL (de novo) was 
proffered. Though a conventional karyotyping could 
not be performed, fluorescence in situ hybridization 
(FISH) was undertaken for t(11;14), which was 
negative. The patient was treated with combination 
chemotherapy with rituximab and bendamustine and 
was doing well after three cycles of chemotherapy, 
with normalization of symptoms and blood counts. 
The patient has been lost to follow-up since then.
Figure 2. Flow cytometric analysis exhibiting predominance of the lymphoid population which was gated on the 
CD 45 vs Forward Scatter vs Side Scatter plot. The gated events (63%) demonstrated a CD 19++, CD 20++, 
CD 22++ clone for light chain kappa and negativity for CD 34, CD 10, CD 103, lambda, surface CD 3, CD 8, CD 4 
(not shown) and CD 11c (not shown).
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DISCUSSION
B-PLL is an extremely rare, clinically aggressive 
lymphoid malignancy usually seen in the advanced age 
(median age of 69 years) with similar incidence in males 
and females. Most patients present with B symptoms 
like fever, night sweats, and weight loss, massive 
splenomegaly without significant lymphadenopathy, 
and marked lymphocytosis (usually > 100 x 109/L) 
with numerous prolymphocytes in the peripheral 
blood (usually > 90%) and bone marrow. Anemia 
and thrombocytopenia are seen in 50% of cases.2,4,5 
Galton et al.6 described a prolymphocyte as a large 
cell with a round nucleus, a prominent vesicular 
nucleolus, condensed nuclear chromatin, and abundant 
cytoplasm. The French-American-British (FAB) group 
subsequently delineated B-PLL as having more than 
55% prolymphocytes of the lymphoid cells in the 
peripheral blood.4 In contrast, CLL is a common, 
clinically indolent neoplasm in which the neoplastic 
cells are small lymphocytes with mature chromatin 
and minimal cytoplasm without nucleoli. However, 
a subset of CLL cases may acquire an increased 
number of prolymphocytes and eventually transform 
into a neoplasm that can resemble those of B-cell 
PLL. These neoplasms have been designated as CLL 
in prolymphocytoid transformation or CLL/PLL.2,7,8 
Both CLL/PL and PLL are characterized by marked 
splenomegaly, and in both, the extent of splenic 
enlargement is proportional to the percentage 
of prolymphocytes. However, there is a striking 
discontinuity between these two groups, because 
lymph-node enlargement is a major feature of 
CLL/PLL but not of PLL. Thus, PLL cannot be considered 
as the extreme end of a continuous spectrum 
from typical CLL.7 Gene expression profiling has 
demonstrated that B-PLL has a signature quite distinct 
from that of CLL or CLL/PLL9 and are biologically 
distinct diseases.
The diagnosis of CLL/PLL is often challenging 
because of the considerable overlap with other 
mature B-cell leukemias and lymphomas (Table 1). 
The differential diagnosis in our context included: 
(A) B-cell type: (i) CLL, (ii) B-PLL, (iii) Hairy cell Leukemia 
(HCL), (iv) HCL Variant (HCL-V), (v) Lymphoma spillover: 
Splenic Marginal Zone Lymphoma (SMZL), Mantle 
Cell Lymphoma (MCL), and Follicular cell lymphoma. 
(B) T-cell type: T-cell PLL. The clinical finding of 
significant generalized lymphadenopathy, as seen 
in our case, is extremely uncommon in B-PLL, SMZL, 
HCL, and HCL-V, which are otherwise the closest 
mimickers given the similar clinical presentation (older 
age, splenomegaly, and lymphocytosis). Thus, the 
aforementioned clue is the most substantial one in 
somewhat excluding these entities. Meticulous scrutiny 
of peripheral blood morphology is one of the keys to an 
accurate diagnosis. The prolymphocyte count must be 
greater than 55% of the lymphoid cells in the peripheral 
blood and usually exceeds 90% in B-PLL, while in CLL 
it is less than 11% and in CLL/PLL, 11-55%.2,6,7 It must 
be firmly borne in mind that the computation has to be 
performed in the peripheral blood and not in the bone 
marrow. Thus, while the count of prolymphocytes in 
our case exceeded 55% in the marrow, but owing to 
its enumeration being 30% of the lymphoid cells in the 
peripheral blood, both B-PLL and CLL were excluded 
morphologically. Moreso, B-PLL presents with a very high 
total leukocyte count with marked lymphocytosis. The 
Figure 3. A – Photomicrograph of bone marrow biopsy revealing diffuse infiltration by dual population of atypical 
lymphoid cells, the prolymphocytes (arrow) and the small lymphocytes. IHC demonstrating reactivity of the lymphoid 
cells for CD 5 in B, and negativity for Cyclin D1 in C (A – H & E, X400; B – X400; C – X100).
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B-prolymphocyte has a characteristic large size, twice 
that of a small CLL lymphocyte. The nuclear chromatin 
is moderately condensed, there is often a prominent 
central nucleolus, and the nuclear outline is typically 
round and more uniform than in CLL. The cytoplasm 
is more abundant than in CLL, clear, and only weakly 
basophilic. The cells of HCL are known to have hairy 
cytoplasmic projections and uniformly lack nucleoli, 
unlike that of prolymphocytes. Peripheral blood atypical 
lymphocyte morphology in SMZL consists of villous 
lymphocytes (polar villi) with basophilic cytoplasm. 
Franco et al.10 reported that bone marrow infiltration 
of the SMZL is mostly of the intrasinusoidal type. The 
closest morphologic differential of prolymphocytes is the 
atypical lymphoid cells of HCL-V, which has intermediate 
properties between HCL and B-PLL. However, in contrast 
to the circulating cells in HCL-V and SMZL, the cytoplasm 
of prolymphocytes generally has a smooth outline.3,4 
Follicular lymphoma with circulating disease can be 
delimited by the cleaved nuclei with irregular contours 
characteristic of centrocytes.3
Although immunophenotyping may support a 
diagnosis of CLL/PLL, a CLL/PLL-specific immunophenotype 
has not been identified yet;11 thus, the diagnosis rests 
mainly on the exclusion of other conditions. The cells in 
CLL/PLL express various pan B-cell antigens with moderate 
intensity (CD 19, CD 20, CD 22, CD 24, CD 79b and FMC 7), 
and surface immunoglobulin (IgM or IgM/IgD) is detected 
at higher levels than in CLL.4 CD 200 is weakly positive or 
negative. The higher intensity of the expressed markers 
helps in differentiating CLL/PLL from CLL, which generally 
has a dim expression of surface Ig, CD 20, and other B-cell 
antigens.1,4,12 CLL/PLL can be CD 23 and CD 5 negative; 
the CD 5 positive cases (as in our context demonstrated 
by IHC), however, may be difficult to differentiate from 
MCL in the leukemic phase.4,12 Herein comes the role of 
Cyclin D1, which was demonstrated to be negative on 
the marrow biopsy by IHC. Moreover, cytogenetic analysis 
of our case did not divulge t(11;14), thus essentially 
ruling out one important mimicker, i.e., MCL. Also, the 
absence of expression of CD 11c, CD 103, and CD 10 
assisted in distinguishing CLL/PLL from HCL, HCL-V, and 
follicular lymphoma. The above-mentioned phenotype 
readily precludes T-PLL, which expectedly expresses T-cell 
markers. The diagnosis of de novo CLL/PLL was tendered 
since the patient did not have any prior documentation 
of lymphocytosis or lymphadenopathy or history of CLL. 
The presentation of generalized lymphadenopathy with 
a mixed hematological picture of small lymphocytes and 
prolymphocytes (30% of lymphoid cells) in the peripheral 
blood, as well as in the bone marrow fitted into none of 
the aforementioned entities other than CLL/PLL.
There is a scarcity of data to guide therapy in 
CLL/PLL cases.13 The regimens used for CLL are often 
employed for treating CLL/PLL. Extrapolating from 
the CLL guidelines, 17p deletion or TP53 mutation 
is considered a high-risk genetic feature and is 
often used to guide therapy. Patients lacking a 17p 
deletion or TP53 mutation are initially treated with 
a combination of fludarabine, cyclophosphamide, 
and rituximab. Conversely, patients with a 17p 
deletion or TP53 mutations inherit primary resistance 
to purine analog/alkylator-based therapy, thus 
making the aforementioned chemotherapeutic 
agents less effective. Case reports have described 
the response of such patients treated with targeted 
drugs including ibrutinib, alemtuzumab, idelalisib, 
and venetoclax.1,4,13,14 Although such regimens with 
superior efficacy are existent, the patient in our study 
was treated with bendamustine-rituximab, in view of 
the financial constraints.
In conclusion, a comprehensive approach involving 
clinical, morphological, and immunophenotypic 
features is extremely vital in this era for diagnosis, 
management, and prognostication. This case, the first 
report of this entity from North East India, documents 
the rare de novo presentation of CLL/PLL and also 
illustrates the impressive utility of ancillary studies such 
as immunophenotyping as an adjunct to morphology 
in the diagnosis of this entity and its distinction from 
other CLPDs.
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